Industry Spotlight: The Man, the Molecule, the Market: Untangling Alzheimer’s Mystery


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

Product Description

Alzheimer’s disease is a progressive brain disorder that damages and eventually destroys brain cells, leading to loss of memory, thinking, and other brain functions. Alzheimer’s is not a part of normal aging, but results from a complex pattern of abnormal changes. It usually develops slowly and gradually worsens as more brain cells wither and die. The underlying causes and processes involved in this harmful deterioration are still under debate within the scientific community.
This spotlight feature article takes a unique look at Alzheimer’s disease. In an exclusive interview, Professor Claude Wischik, M.D., Ph.D., executive chairman and co-founder of TauRx Therapeutics and professor of Old Age Psychiatry at the University of Aberdeen, discusses his 30-year journey of tau research, the divergent scientific views on the role of beta amyloid and tau pathology in Alzheimer’s, and what success from TauRx’s upcoming Phase III clinical trials denotes for…

Alzheimer’s Facts
Pipeline Analysis by Clinical Phase
Alzheimer’s timeline

Professor Claude Wischik, M.D., Ph.D.
, executive chairman and co-founder of TauRx Therapeutics.